+500%

est. 2Y upside i

Healthcare

Rank

#6

Sector

Healthcare & Life Sciences

Est. Liquidity

~3Y

Data Quality

Data: Low

The equity offer appears astronomically undervalued due to a stale 2021 valuation mark, producing a +1369% expected upside if the company's true market value is recognized.

Last updated: August 21, 2026

Bull (25%)+200%

Projected revenue of $155.5M (28% growth, decaying) supports a 9x forward multiple, valuing the company at $1.4B and implying a 31x return on the $43.5M entry. Per Series C+ stage constraints, the reported upside is capped at +200% to temper the extreme optimism from the stale 2021 valuation.

Base (55%)+2045%

Revenue reaches $155.5M and the exit multiple compresses to 6x, in line with public comps, yielding a $933M valuation — a 20.5x return. This assumes a fresh funding round corrects the outdated $43.5M mark and that the company continues on its 28% growth trajectory.

Bear (20%)+972%

Revenue growth slows to ~15% and the multiple falls to 3x, valuing the company at $466.5M, still above the $145M preferred liquidation stack, leaving common stock with $321.5M in proceeds. This is a 9.7x company-level return, but the actual common recovery is beset by preference overhang and illiquidity.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

33333%

Total funding of $145M is 3.3x the current $43.5M valuation, meaning preferred shareholders hold liquidation preferences far exceeding the company's worth.

Dilution Risk

low

The company is profitable with $110M revenue, and the latest round in Dec 2024 should provide ample runway; no significant dilution expected in the 2-year horizon.

Secondary Liquidity

none

There is no secondary market for private shares and no IPO signals, making liquidity highly uncertain.

View all 71 open roles at Carestack →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Carestack's data — designed to show you've done your homework.

  • 1

    “How does CareStack plan to deploy the $60M raised in Dec 2024, and when can we expect the next formal valuation mark?”

  • 2

    “With revenue at $110M and profitability, what is the company's capital allocation strategy — will it raise, acquire, or focus on organic growth?”

  • 3

    “Can you outline the option pool size and historical dilution, and how a potential future round might affect employee ownership over the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates +500% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.